Flashback to the EXPO: Startup Creasphere Meets The Swiss Innovation Ecosystem, where Volv Global SA was present as one of the flagship innovative companies in Switzerland. Based at the Biopôle Lausanne, we focus on finding those patients that clinicians find difficult to recognise and typically remain undiagnosed. We arrived at this innovation, starting out from a real medical and (pharma) business problem statement that is common, not only in the rare disease space, but in many other more common indications: for many diseases, patients experience long diagnostic delays. One of our first customers had a drug in market for a disease with a prevalence of 4 per million, but only ever found 1. So, this is the basic problem we solve for. But we have now further refined our capabilities to find such patients significantly, demonstrably sooner than they might normally be diagnosed in clinical practice. And this is particularly important when dealing with progressive diseases. Also, we have developed methods to predict which patients are likely to progress quicker than others, so we can help direct focus, attention and often limited healthcare resources, to those that may need them most urgently. Want to learn more about what we do? How this helps HCPs improve patient care and optimise clinical workflows? The ways we help drug development companies accelerate their development programs? And support the commercial lifecycle of drugs in market for difficult to diagnose diseases? Contact us today! #inTrigue #inVolv #raredisease #diagnosis #aiinhealthcare #aiinnovation Biopôle Lausanne STARTUP CREASPHERE powered by Plug and Play Switzerland Innovation Park Basel Area Basel Area Business & Innovation Innosuisse
Leon van Wouwe’s Post
More Relevant Posts
-
🌟 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀 𝗳𝗼𝗿 𝗟𝘆𝗺𝗽𝗵𝗲𝗱𝗲𝗺𝗮 𝗖𝗮𝗿𝗲! Join us in celebrating 𝗟𝘆𝗺𝗽𝗵𝗮𝘁𝗶𝗰𝗮 𝗠𝗲𝗱𝘁𝗲𝗰𝗵, a clinical-stage innovator from Lausanne, for closing a €17.9 million Series B funding round! This investment will accelerate the development of LymphoDrain, a pioneering implantable device set to transform care for millions with lymphedema. 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: - Strategic Partnerships. - Leadership Boost. - Global Vision. Founded in 2017 as an EPFL and CHUV spin-off, Lymphatica Medtech is dedicated to revolutionizing treatment for lymphatic diseases. Early results are promising, and with a strong board and investor backing, the future is brighter than ever. More insights: https://swiy.co/Q5Zh #medtech #lymphedema
To view or add a comment, sign in
-
🌟 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀 𝗳𝗼𝗿 𝗟𝘆𝗺𝗽𝗵𝗲𝗱𝗲𝗺𝗮 𝗖𝗮𝗿𝗲! Join us in celebrating 𝗟𝘆𝗺𝗽𝗵𝗮𝘁𝗶𝗰𝗮 𝗠𝗲𝗱𝘁𝗲𝗰𝗵, a clinical-stage innovator from Lausanne, for closing a €17.9 million Series B funding round! This investment will accelerate the development of LymphoDrain, a pioneering implantable device set to transform care for millions with lymphedema. 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: - Strategic Partnerships. - Leadership Boost. - Global Vision. Founded in 2017 as an EPFL and CHUV spin-off, Lymphatica Medtech is dedicated to revolutionizing treatment for lymphatic diseases. Early results are promising, and with a strong board and investor backing, the future is brighter than ever. More insights: https://swiy.co/Q5Zh #medtech #lymphedema
🌟 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀 𝗳𝗼𝗿 𝗟𝘆𝗺𝗽𝗵𝗲𝗱𝗲𝗺𝗮 𝗖𝗮𝗿𝗲! Join us in celebrating 𝗟𝘆𝗺𝗽
swiy.co
To view or add a comment, sign in
-
🌟 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀 𝗳𝗼𝗿 𝗟𝘆𝗺𝗽𝗵𝗲𝗱𝗲𝗺𝗮 𝗖𝗮𝗿𝗲! Join us in celebrating 𝗟𝘆𝗺𝗽𝗵𝗮𝘁𝗶𝗰𝗮 𝗠𝗲𝗱𝘁𝗲𝗰𝗵, a clinical-stage innovator from Lausanne, for closing a €17.9 million Series B funding round! This investment will accelerate the development of LymphoDrain, a pioneering implantable device set to transform care for millions with lymphedema. 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: - Strategic Partnerships. - Leadership Boost. - Global Vision. Founded in 2017 as an EPFL and CHUV spin-off, Lymphatica Medtech is dedicated to revolutionizing treatment for lymphatic diseases. Early results are promising, and with a strong board and investor backing, the future is brighter than ever. More insights: https://swiy.co/Q5Zh #medtech #lymphedema
🌟 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀 𝗳𝗼𝗿 𝗟𝘆𝗺𝗽𝗵𝗲𝗱𝗲𝗺𝗮 𝗖𝗮𝗿𝗲! Join us in celebrating 𝗟𝘆𝗺𝗽
swiy.co
To view or add a comment, sign in
-
🔔 #BIOMAN4R2 𝙎𝙐𝘾𝘾𝙀𝙎𝙎 𝙎𝙏𝙊𝙍𝙄𝙀𝙎 🇪🇺 The COVID-19 pandemic highlighted challenges and risks in #EU health supply chains. In response, the 𝐁𝐢𝐨𝐌𝐚𝐧𝟒𝐑𝟐 #Eurocluster aimed to adapt existing health sector funding to scale up innovation. The direct objective of 𝐁𝐢𝐨𝐌𝐚𝐧𝟒𝐑𝟐 is to foster long-term collaboration at the EU level among SMEs, investors, research organizations, and others in the #biomanufacturing and #medtech industries through a Eurocluster and 𝙎𝙈𝙀 𝙎𝙪𝙥𝙥𝙤𝙧𝙩 𝙋𝙧𝙤𝙜𝙧𝙖𝙢𝙢𝙚.💰 ⏩ Check out our #1 Success Story: 🏅 Oniria Therapeutics was one of the awarded companies within the 𝘽𝙐𝙎𝙄𝙉𝙀𝙎𝙎 𝙏𝙍𝘼𝙉𝙎𝙁𝙊𝙍𝙈𝘼𝙏𝙄𝙊𝙉 category: a biotech company focused on the development of first-in-class drugs in the field of precision #oncology. They aim to fight against the persistence of #tumour recurrence by pioneering a novel targeted strategy against the epigenetic enzyme TET2. "𝐁𝐢𝐨𝐌𝐚𝐧𝟒𝐑𝟐 𝘩𝘢𝘴 𝘩𝘦𝘭𝘱𝘦𝘥 𝘵𝘰 𝘢𝘯𝘢𝘭𝘺𝘴𝘦 𝘵𝘩𝘦 𝘨𝘢𝘱 𝘣𝘦𝘵𝘸𝘦𝘦𝘯 𝘵𝘩𝘦 𝘱𝘳𝘰𝘥𝘶𝘤𝘵 𝘱𝘰𝘴𝘪𝘵𝘪𝘰𝘯𝘪𝘯𝘨 𝘢𝘯𝘥 𝘵𝘩𝘦 𝘦𝘹𝘱𝘦𝘤𝘵𝘦𝘥 𝘦𝘷𝘪𝘥𝘦𝘯𝘤𝘦 𝘱𝘢𝘤𝘬𝘢𝘨𝘦 𝘳𝘦𝘲𝘶𝘪𝘳𝘦𝘥 𝘵𝘰 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘩𝘦𝘢𝘭𝘵𝘩 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘢𝘴𝘴𝘦𝘴𝘴𝘮𝘦𝘯𝘵 𝘴𝘶𝘣𝘮𝘪𝘴𝘴𝘪𝘰𝘯𝘴, 𝘰𝘱𝘵𝘪𝘮𝘪𝘻𝘪𝘯𝘨 𝘵𝘩𝘦 𝘮𝘢𝘳𝘬𝘦𝘵 𝘢𝘤𝘤𝘦𝘴𝘴/𝘱𝘳𝘪𝘤𝘪𝘯𝘨 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘺 𝘣𝘦𝘧𝘰𝘳𝘦 𝘤𝘩𝘰𝘰𝘴𝘪𝘯𝘨 𝘵𝘩𝘦 𝘤𝘰𝘶𝘯𝘵𝘳𝘪𝘦𝘴 𝘸𝘩𝘦𝘳𝘦 𝘵𝘩𝘦 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘵𝘳𝘪𝘢𝘭 𝘸𝘪𝘭𝘭 𝘣𝘦 𝘤𝘰𝘯𝘥𝘶𝘤𝘵𝘦𝘥. 𝘐𝘵 𝘢𝘭𝘴𝘰 𝘩𝘦𝘭𝘱𝘦𝘥 𝘶𝘴 𝘵𝘰 𝘥𝘦𝘧𝘪𝘯𝘦 𝘵𝘩𝘦 𝘤𝘰𝘶𝘯𝘵𝘳𝘪𝘦𝘴 𝘧𝘰𝘳 𝘰𝘶𝘳 𝘗𝘊𝘛 𝘱𝘢𝘵𝘦𝘯𝘵 𝘦𝘯𝘵𝘦𝘳𝘴 𝘕𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘗𝘩𝘢𝘴𝘦𝘴." We would like to express our gratitude to Oniria Therapeutics for their valuable testimonial. 🙏 Congratulations for your achievements! 🎉 #resilience #europeanunion #biotech #innovation #startup #EUfunding Vall d'Hebron Institute of Oncology (VHIO), Universitat de Barcelona ICREA - Institució Catalana de Recerca i Estudis Avançats Esther Riambau Natalia Ricco Elsa Martínez Arce, Ph.D. Turku Science Park Ltd Council of European BioRegions - CEBR Biocat, BioRegion of Catalonia BioRegio STERN Management GmbH MedSilesia Cluster - Silesian Medical Devices Network Medicen Paris Region LifetecZONe
To view or add a comment, sign in
-
CHF 14 Million to advance life-saving blood purification technology: TOP 100 Swiss startup hemotune AG raises Series B2 funding. Congrats and best of success onwards to Lukas Langenegger and his team of medtech innovators! https://lnkd.in/dWQ9kGxf The investment was led by Belmondo and existing investors including VP Venture Partners, HEMEX, OCCIDENT, Zürcher Kantonalbank, and joined by EFI. About: hemotune AG is developing a revolutionary medical device for blood purification that combines cutting-edge scientific results from biomedicine and nanotechnology. It allows specific and direct removal of disease-causing substances from the blood stream of a patient. The technology targets a broad range of harmful compounds such as toxins, pathogenic organisms, or overdosed drugs. Moreover, by being more targeted, efficient, and gentler than previous blood filters, we outperform state of the art therapies and improve patient outcomes. Hemotune is a 2017 alumnus of Venture Kick and three-time laureate of the TOP 100 Swiss Startup Award. #VentureKick #SwissStartups #TOP100SSU
Hemotune secures CHF 14 Million in Series B2 Funding to advance innovative blood purification technology
venturekick.ch
To view or add a comment, sign in
-
🌍 The Basel Area: Europe's Silicon Valley of Biotech Innovation The Basel Area is rapidly positioning itself as the Silicon Valley of Biotech, blending cutting-edge innovation with a thriving life sciences ecosystem. With over 700 startups, SMEs and biotech giants like #Roche and #Novartis, the region is becoming a magnet for top talent, groundbreaking research and venture capital investment. 🧬 Key Highlights: 🏢 Home to 31,000+ employees across biotech, digital health and advanced manufacturing 📈 Backed by leading investors like Novartis Venture Fund and Roche Venture Fund 🧪 Thriving research in oncology, immunology, infectious diseases and more 🏆 Supported by BaseLaunch, a premier incubator fueling biotech startups, and the leading healthtech accelerator DayOne - Healthcare Innovation With its combination of scientific excellence, political stability and strong collaboration between academia and industry, the region is set to lead the future of global biotech innovation. Read more to explore what the future holds: https://buff.ly/3VZNfHo ---- Follow us on #discoverthebaselarea Basel Area Business & Innovation #Biotech #Innovation #LifeSciences #BaselArea
To view or add a comment, sign in
-
Focused on our main goal to build a solid Bridge of Collaboration between Boston Biotech Ecosystem and France, we EXPANDED our presence and actions in September in France. Meeting the CEOs and discussing plans & opportunities, making meaningful connections, comprehending the challenges, having an overview of the investment options as well as the future of the Healthcare in France, were absolutely essential in order to prepare the 9th Boston Paris Biotechnology Summit™ in 2025. Stay Tuned! Thank you Sophie Villedieu, Pierre Courteille and @HTID team in Paris. HealthTech For Care, a non-for-profit organization, organizes the HealthTech Innovation Days (HTID), a pivotal European event serving as a platform for innovation and science stakeholders. Thank you Gencovery, Djomangan Adama OUATTARA, and Constellab in Lyon, an open and secure digital platform offering flexible solutions for leveraging AI and data to enhance R&D, services, and production in the life sciences industry. Thank you to all excellent professionals and experts we met in France. See you in Boston in June 2025! Shahin Gharakhanian, MD Ben Wills Mehdi Chelbi French Tech Boston McDermott Will & Emery ICOSA Cilcare Jean-Philippe NICOLAI Business France Healthcare - North America Marie-Astrid Sevilla Jerome Revole Horiana Jennifer A. Bock Vanessa Elharrar MD MPH ESCP Business School #biotech #digitalhealth #medtech #pharma #KOL #investors #Francebiotech
To view or add a comment, sign in
-
Are Digital Therapeutics Dead? ABHI Executive Director, Digital Health Andrew Davies attended the HLTH Europe Startup Stage where the future of this industry was a hot topic💡 Some Digital Therapeutics businesses have ceased to operate, but that is to be expected from an immature sector as innovators find their feet and discover the value of their product. 📈 However, there is an increasing number of new and exciting products for the Digital Therapeutics industry and as maturity continues, we will continue to see more innovative solutions developed. There must be flexibility depending on disease state, modality, and geography and, critically, value must be proven! How else can the Digital Therapeutics business model be made more sustainable? Visit our resource hub for insightful reports, whitepapers and webinars designed to assist the growth of HealthTech SMEs 👉 https://lnkd.in/eXDUAMPb #Innovation #Healthcare #HLTH #medtech #digitalhealth #healthtech
To view or add a comment, sign in
-
🚀 Any news from #biotechnology in #Bavaria? Surely! 📚 We're proud to be mentioned in the latest report "𝗕𝗜𝗢𝗧𝗘𝗖𝗛 𝗜𝗡 𝗕𝗔𝗩𝗔𝗥𝗜𝗔 – 𝗜𝗡𝗖𝗨𝗕𝗔𝗧𝗜𝗡𝗚 𝗦𝗖𝗜𝗘𝗡𝗖𝗘 𝗙𝗢𝗥 𝗛𝗘𝗔𝗟𝗧𝗛 ," by BioM Biotech Cluster Development GmbH, highlighting the key players and innovations driving the industry forward. 👇 Click below for all the latest insights!
What is going on in #BavarianBiotechnology? How has it developed over the past year? What are the topics that move the players in #Bigpharma, SMEs, academia, #LifeSciences and #Venturecapital? Who has founded, who has merged, who has taken big steps in the development of new #therapeutics, #therapies, (digital) platform #technologies and financing? The latest biotech report 📘„BIOTECH IN BAVARIA – INCUBATING SCIENCE FOR HEALTH“ gives you the answers and insights! ➡️ https://lnkd.in/d-c4iSmn Here you will find: 👉 Current numbers in #biopharma sector: companies, employment, #funding & #financing, startups and clinical #drug pipeline 👉 Current sentiment on the #businessclimate and #AI of the biotech and pharmaceutical industry in Bavaria, Germany and Europe 👉 Interviews with Prof. Ralf Huss of BioM Biotech Cluster Development GmbH, Prof. Claudia Traidl-Hoffmann of Universität Augsburg/Helmholtz Munich and Prof. Matthias H. Tschöp of Helmholtz Munich/Technische Universität München 👉 Success Stories of #startups Tubulis GmbH and Ebenbuild 👉 Voices, advice and experiences on founding from the academy through the eyes of #founders, accelerators and #investors 👉 Driving Investments of Roche Deutschland, Minaris Regenerative Medicine, Daiichi Sankyo Europe GmbH und MSD with affirmation of #Bavaria as a global biotech hub 👉 Introducing BioM’s new incubator „Munich Accelerator Life Sciences & Medicine“ #MAxL, featuring #preseed teams RNATICS and Leopard Biosciences 👉 More insights on projects of the key players, stakeholders and #lifesciencehubs in Bavarian biotechnology from Invest in Bavaria - The Business Promotion Agency of the State of Bavaria, #DigiMedBayern, BioPark Regensburg GmbH, Innovations- und Gründerzentrum (IGZ) Würzburg, Medical Valley EMN e. V. and the IZB - Innovation and Start-up Center Biotechnology! 👉 > 300 #companyprofiles #Biotechreport #InnovationinBavaria #BavarianBiotechnologyCluster
To view or add a comment, sign in
-
🚀 We're gearing up for the presentation of the #BioRegionReport 2025! This presentation will kick off the #BCNHealthInnovation Week. Over 700 professionals attended last year's edition. Are you going to miss it? 📅 When: 17/02/25 📍 Where: Auditori l'Illa 👉 Register now: https://lnkd.in/demWi7At 📝 The #BioRegionCatalonia Report, published by #Biocat since 2009, has become the most solid and wide-reaching analysis of the assets, achievements and trends in the life sciences and healthcare sector in Catalonia within an international framework. 🔎 As we prepare for the 2024 edition, let’s take a moment to reflect on some of the standout achievements from the #BioRegionReport 2023, which highlighted Catalonia as one of the most dynamic and competitive hubs for health innovation in Europe: ✔ Health startups and scaleups in Catalonia raised €220 million in 2023. ✔ Catalonia ranks among the top 10 globally for clinical trial participation, placing 5th in Europe and 8th worldwide. ✔ Catalonia saw €1.025 billion in foreign investment—a 110% increase from the previous year, with the new AstraZeneca hub playing a key role in this growth. This event is proudly supported by our sponsors and collaborators, who are key to making the #BioRegionReport possible: Alira Health AstraZeneca Johnson & Johnson Menarini España Roche Amgen España Almirall ESTEVE Pfizer Sanofi ACCIÓ Catalonia.Health (CataloniaBio & HealthTech) Farmaindustria Fenin, Federación Española de Empresas de Tecnología Sanitaria
To view or add a comment, sign in